Jak ograniczyć ślad węglowy inhalatorów ciśnieniowych dozujących ? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2022
Słowa kluczowe:
inhalatory ciśnieniowe dozujące (pMDI), hydrofluoroalkany, ślad węglowy, cieplarniany efekt emisji
##plugins.themes.bootstrap3.article.main##
Abstrakt
Inhalatory ciśnieniowe dozujące (pMDI) postawiają największy ślad węglowy spośród wszystkich indywidualnych urządzeń inhalacyjnych. W największym stopniu zależy on zastosowanych propelentów. Inhalator pMDI z propelentem typu HFA 227a pozostawia 2-3 krotnie większy ślad węglowy niż pMDI z HFA 134a. Ograniczenie śladu węglowego pMDI może się dokonać poprzez redukcję preskrypcji leków w pMDI na rzecz inhalatorów suchego proszku (DPI), wprowadzenie powszechnego recyklingu inhalatorów, zmianę formulacji niektórych leków, czy wprowadzenie nowych propelentów w pMDI o niskim potencjale cieplarnianym. Najbardziej zaawansowane prace dotyczą HFA 152a. Przewiduje się, że inhalatory pMDI z HFA 152a będą miały ślad węglowy zbliżony do przeciętnego DPI.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Emeryk , A., Emeryk-Maksymiuk , J., & Sosnowski , T. R. (2022). Jak ograniczyć ślad węglowy inhalatorów ciśnieniowych dozujących ? . Alergoprofil, 18(1), 14-20. https://doi.org/10.24292/01.AP.181100322
Numer
Dział
THERAPY
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Dane z farmaceutycznej bazy danych, IQVIA 2020-2021 sell in.
2. Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS Pharm Sci Tech. 2014; 15: 434-55.
3. PRODUCT INFORMATION. QVAR. (access: 10.10.2021).
4. Baron Ch. Is now the time to shake up the pMDI environment? Pulm Nasal Drug Deliv. 2020; 106: 1013.
5. Acerbi D, Brambilla G, Kottakis I et al. Advances in asthma and COPD management: Delivering CFC-free inhaled therapy using Modulite® technology. Pulm Pharmac Ther. 2007; 20: 290-303.
6. Scichilone N, Spatafora M, Battaglia S et al. Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations. J Asthma Allergy. 2013; 6: 11-21.
7. De Backer W, Devolder A, Poli G et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010; 23(3): 137-48.
8. Leach Ch, Colice GL, Luskin A. Particle size of inhaled corticosteroids: Does it matter? J Allergy Clin Immunol. 2009; 124: S88-S93.
9. Peters GP. Carbon footprints and embodied carbon at multiple scale. Curr Opin Environ Sustain. 2010; 2: 245-50.
10. IPCC 2001. Climate Change 2001: The Scientific Basis. Contribution of Working Group I to the Third Assessment Report of the Intergovernmental Panel on Climate Change. Houghton JT, Ding Y, Griggs DJ et al (ed). Cambridge University Press, Cambridge, United Kingdom and New York, NY, USA.
11. EPA, 2020. (access: 10.10.2021).
12. Goulet B, Olson L, Mayer KB. A comparative life cycle assessment between a metered dose inhaler and electric nebulizer. Sustainability. 2017; 9: 1725.
13. http://www.ondrugdelivery.com (access: 10.10.2021).
14. Hansel M, Bambach T, Wachtel H. Reduced environmental impact of the reusable Respimat soft mist inhaler compared with pressurized metered-dose inhalers. Adv Ther. 2019; 36: 2487-92.
15. The Problem with Inhalers. (access: 25.11.2021).
16. Janson Ch, Henderson R, Löfdahl M et al. Carbon footprint impact of the choice of inhalers for asthma and COPD. Thorax. 2020; 75: 82-4.
17. Panigone S, Sandri F, Ferri R et al. Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment. BMJ Open Resp Res. 2020; 7: e000571.
18. Mueller-Walz R, Fueg LM. Medicinal aerosol formulations, 2014. (access: 2.12.2021).
19. Atherton M. Environmental impact of inhalers, 2017. (access: 27.09.2021).
20. Some Specific Inhalers – Ventolin™, Flutiform™, Symbicort™ MDI . (access:10.10.2021).
21. Emeryk WA, Sosnowski T, Kupczyk M et al. Impact of inhalers used in the treatment of respiratory diseases on global warming. Adv Respir Med. 2021; 89(4): 427-38.
22. British Lung Foundation (2019). Which inhalers are kindest to the environment . (access: 10.10.2021).
23. Hillman T, Mortimer F, Hopkinson N. Inhaled drugs and global warming: time to shift to dry powder inhalers. BMJ. 2013; 346: f3359.
24. Bouley T, Boykoff M, Byass P et al. Climate-smart healthcare: low-carbon and resilience strategies for the health sector. Washington, DC: World Bank Group. 2017. (access: 22.10.2021).
25. Kigali Amendment, information note (February 2017) . (access: 10.10.2021).
26. Wilkinson AJK, Braggins R, Steinbach I et al. Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England. BMJ Open. 2019; 9(10): e028763.
27. Płusa T, Badowska-Kozakiewicz A. Carbon footprint of inhalers in COPD therapy in 2018 and 2019 in Poland in response to the Kigali amendment. Pol Merk Lek. 2020; 48: 391-3.
28. Płusa T, Badowska-Kozakiewicz A. Can we minimize carbon footprint by using “greener” inhalers and improve clinical outcome at the same time in asthma therapy? Pol Merk Lek. 2021; 49: 252-4.
29. Emeryk A, Pirożyński M, Mazurek H et al. Polski przewodnik inhalacyjny. 2nd ed. Via Medica, Gdańsk 2021: 1-33.
30. Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019; 15: 461-72.
31. Mahler DA. The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease. Respir Med. 2020; 161: 105857.
32. Fuglo-Mortensen R, Lange P, Mortensen J. Inhalers and inhalation techniques in the treatment of asthma and chronic obstructive pulmonary disease. Ugeskr Laeger. 2019; 181(33): 5-9.
33. Rogliani P, Calzetta L, Coppola A et al. Optimizing drug delivery in COPD: the role of inhaler devices. Respir Med. 2017; 124: 6-14.
34. Jeswani HA, Azapagic A. Life cycle environmental impacts of inhalers. J Clean Prod. 2019; 237.
35. Pritchard JN. The climate is changing for metered-dose inhalers and action is needed. Drug Des Devel Ther. 2020; 14: 3043-55.
36. Jeswani H, Azapagic A. Environmental assessment of metered dose inhaler propellant: potential for a reduced carbon footprint alternative. Respir Drug Deliv Europe. 2017. Abstract.
37. Corr S, Noakes T. Pressurised metered dose inhaler propellants: going forward. Respir Drug Deliv Europe. 2017. Abstract.
38. Press Release, Chiesi, December 4, 2019. Chiesi outlines €350 million investment and announces the development of the first carbon minimal pressurised Metered Dose Inhaler (pMDI) for Asthma and COPD.
39. We ACT Day 2019: Chiesi sets itself the challenge of becoming carbon neutral by 2035 (access:10.10.2021).
40. Brambilla G, Johnson R, Lewis DA. Aerosol inhalation device, 2014. (access: 30.10.2021).
41. Brown M, Jones S, Martin G. Metered dose inhalation preparations of therapeutic drugs, 2010. (access: 21.11.2021).
2. Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS Pharm Sci Tech. 2014; 15: 434-55.
3. PRODUCT INFORMATION. QVAR. (access: 10.10.2021).
4. Baron Ch. Is now the time to shake up the pMDI environment? Pulm Nasal Drug Deliv. 2020; 106: 1013.
5. Acerbi D, Brambilla G, Kottakis I et al. Advances in asthma and COPD management: Delivering CFC-free inhaled therapy using Modulite® technology. Pulm Pharmac Ther. 2007; 20: 290-303.
6. Scichilone N, Spatafora M, Battaglia S et al. Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations. J Asthma Allergy. 2013; 6: 11-21.
7. De Backer W, Devolder A, Poli G et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010; 23(3): 137-48.
8. Leach Ch, Colice GL, Luskin A. Particle size of inhaled corticosteroids: Does it matter? J Allergy Clin Immunol. 2009; 124: S88-S93.
9. Peters GP. Carbon footprints and embodied carbon at multiple scale. Curr Opin Environ Sustain. 2010; 2: 245-50.
10. IPCC 2001. Climate Change 2001: The Scientific Basis. Contribution of Working Group I to the Third Assessment Report of the Intergovernmental Panel on Climate Change. Houghton JT, Ding Y, Griggs DJ et al (ed). Cambridge University Press, Cambridge, United Kingdom and New York, NY, USA.
11. EPA, 2020. (access: 10.10.2021).
12. Goulet B, Olson L, Mayer KB. A comparative life cycle assessment between a metered dose inhaler and electric nebulizer. Sustainability. 2017; 9: 1725.
13. http://www.ondrugdelivery.com (access: 10.10.2021).
14. Hansel M, Bambach T, Wachtel H. Reduced environmental impact of the reusable Respimat soft mist inhaler compared with pressurized metered-dose inhalers. Adv Ther. 2019; 36: 2487-92.
15. The Problem with Inhalers. (access: 25.11.2021).
16. Janson Ch, Henderson R, Löfdahl M et al. Carbon footprint impact of the choice of inhalers for asthma and COPD. Thorax. 2020; 75: 82-4.
17. Panigone S, Sandri F, Ferri R et al. Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment. BMJ Open Resp Res. 2020; 7: e000571.
18. Mueller-Walz R, Fueg LM. Medicinal aerosol formulations, 2014. (access: 2.12.2021).
19. Atherton M. Environmental impact of inhalers, 2017. (access: 27.09.2021).
20. Some Specific Inhalers – Ventolin™, Flutiform™, Symbicort™ MDI . (access:10.10.2021).
21. Emeryk WA, Sosnowski T, Kupczyk M et al. Impact of inhalers used in the treatment of respiratory diseases on global warming. Adv Respir Med. 2021; 89(4): 427-38.
22. British Lung Foundation (2019). Which inhalers are kindest to the environment . (access: 10.10.2021).
23. Hillman T, Mortimer F, Hopkinson N. Inhaled drugs and global warming: time to shift to dry powder inhalers. BMJ. 2013; 346: f3359.
24. Bouley T, Boykoff M, Byass P et al. Climate-smart healthcare: low-carbon and resilience strategies for the health sector. Washington, DC: World Bank Group. 2017. (access: 22.10.2021).
25. Kigali Amendment, information note (February 2017) . (access: 10.10.2021).
26. Wilkinson AJK, Braggins R, Steinbach I et al. Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England. BMJ Open. 2019; 9(10): e028763.
27. Płusa T, Badowska-Kozakiewicz A. Carbon footprint of inhalers in COPD therapy in 2018 and 2019 in Poland in response to the Kigali amendment. Pol Merk Lek. 2020; 48: 391-3.
28. Płusa T, Badowska-Kozakiewicz A. Can we minimize carbon footprint by using “greener” inhalers and improve clinical outcome at the same time in asthma therapy? Pol Merk Lek. 2021; 49: 252-4.
29. Emeryk A, Pirożyński M, Mazurek H et al. Polski przewodnik inhalacyjny. 2nd ed. Via Medica, Gdańsk 2021: 1-33.
30. Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019; 15: 461-72.
31. Mahler DA. The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease. Respir Med. 2020; 161: 105857.
32. Fuglo-Mortensen R, Lange P, Mortensen J. Inhalers and inhalation techniques in the treatment of asthma and chronic obstructive pulmonary disease. Ugeskr Laeger. 2019; 181(33): 5-9.
33. Rogliani P, Calzetta L, Coppola A et al. Optimizing drug delivery in COPD: the role of inhaler devices. Respir Med. 2017; 124: 6-14.
34. Jeswani HA, Azapagic A. Life cycle environmental impacts of inhalers. J Clean Prod. 2019; 237.
35. Pritchard JN. The climate is changing for metered-dose inhalers and action is needed. Drug Des Devel Ther. 2020; 14: 3043-55.
36. Jeswani H, Azapagic A. Environmental assessment of metered dose inhaler propellant: potential for a reduced carbon footprint alternative. Respir Drug Deliv Europe. 2017. Abstract.
37. Corr S, Noakes T. Pressurised metered dose inhaler propellants: going forward. Respir Drug Deliv Europe. 2017. Abstract.
38. Press Release, Chiesi, December 4, 2019. Chiesi outlines €350 million investment and announces the development of the first carbon minimal pressurised Metered Dose Inhaler (pMDI) for Asthma and COPD.
39. We ACT Day 2019: Chiesi sets itself the challenge of becoming carbon neutral by 2035 (access:10.10.2021).
40. Brambilla G, Johnson R, Lewis DA. Aerosol inhalation device, 2014. (access: 30.10.2021).
41. Brown M, Jones S, Martin G. Metered dose inhalation preparations of therapeutic drugs, 2010. (access: 21.11.2021).